Variable

LTFU (n = 100) n(%)

No LTFU (n = 100) n(%)

OR

CI

p-value

Context of diagnosis

Clinical visit

73 (73)

92 (92)

0.235

0.101-0.548

0.001

Voluntary Counselling and Testing

27 (27)

8 (8)

Eligibility criteria for initiation

Clinical presentation + CD4

79 (79)

73 (73)

1.391

0.724-2.673

0.408

Test and treat

21 (21)

27 (27)

WHO stage

Stage I and II

58 (58)

71 (71)

0.564

0.314-1.014

0.076

Stage III and IV

42 (42)

29 (29)

Mean BMI

24.3 ± 4.2

25.8 ± 4.1

1.105

0.01

Place of treatment initiation

Same facility

99 (99)

98 (98)

2.02

0.180-22.645

1

Different facility

1 (1)

2 (2)

Median CD4 count at initiation

298 (153-438)

298 (165-405)

0.808

Median First viral load

316 (60-3,124)

166 (60-700)

0.147

Median Last viral load (n = 11)

795 (45-7,474)

40 (440-40)

0.376

Treatment line

First-line treatment

97 (97)

100 (100)

0.246

Second-line treatment

3 (3)

0 (0.0)

Mean Number of doses per day

1 ± 1

1 ± 1

-0.262

1

Reported side effects

52 (52)

26 (26)

3.083

1.701-5.588

0

Opportunistic infections

20 (20)

5 (5)

4.75

1.706-13.227

0.003

Other treatment

21 (21)

8 (8)

3.057

1.283-7.282

0.016

Median Duration of psychosocial follow-up

19.5 (9.5-31.5)

33.0 (22.0-51.0)

0

Mean Number of routine adherence counseling sessions

3 ± 1

5 ± 2

-0.787

0

Patient enrolment in a support group

14 (14)

46 (46)

0.191

0.096-0.380

0